Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba® When Administered to Immunocompromised Participants ≥10 Years of Age
Final Report – A Phase 4, Open-Label, Single-Arm Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba® When Administered to Immunocompromised Participants ≥10 Years of Age
Category & Conditions: Infections and Infectious Diseases
Medicine: TRUMENBA™(MENINGOCOCCAL GROUP B VACCINE)
Protocol ID: B1971060
PrintDownload